HEALTH - FOOD

QUERCETIN, MADE BETTERQUERCEFITQUERCETIN PHYTOSOME®

Please note this documentation is available for various countries all over the world and hence it may containstatements or product classification not applicable to your country. The claims made are in reference toingredients only, hence they do not refer to finished products and they may not comply with Regulation ECn. 1924/2006. The marketer of any finished product containing any ingredient is responsible for assuringthat the destination of the product and the claims made for the finished product are lawful and complywith all applicable laws and regulations of the country or countries in which the product is to be sold.

®

W H A T _ I S _ Q U E R C E F I T ®?
QUERCEFIT® is the patent pending1 food grade delivery system of quercetin from Sophorajaponica L., formulated with Phytosome® proprietary technology to optimize the biologicalabsorption of the flavonoids, supporting the overall wellbeing in many conditions. Comparedto the unformulated quercetin, bioabsorption and solubility are greatly optimized so it canbe used at lower dosages retaining its efficacy.2IMMUNITY HEALTH, SENOLYTIC FUNCTION AND COVID-19
Human studies3,4 show that QUERCEFIT® helps maintaining immune system
health and modulates cytochines cascade, thus improving the conditions of
those exposed to Covid-19, precisely thanks to its senolytic function: the productsupplementation helps the health condition of people in the initial phases ofSARS-CoV-2, without substituting the standard treatments envisaged by themedical protocols. In fact, the severity of illness often depends by the way theinitial phases are faced.
A recent human study5 involving 120 high exposure healthcare workers show thatQUERCEFIT® supplementation helps maintaining health conditions in 75% people
working in a COVID-19 infectious environment.
The completion of a preliminary investigation6 on human health support in caseof Covid-19 infection - now performed on 100 subjects - confirmed that just after
one week, the administration of QUERCEFIT® in addition to the Standard Caresignificantly increased clearance of the virus (68% QUERCEFIT® vs 24% StandardCare), reduced symptoms occurrence (52% QUERCEFIT® vs 24% Standard Care),improved crucial biomarkers (great optimization in particular for LDH).
Such evidences show once more the efficacy of quercetin, formulated withPhytosome® delivery system, in being a favourable supplementation in situations
where possible exposition to SARS-CoV-2 risks is higher.

THE NATURAL REMEDY IN THE ALLERGY ERA
A recent randomized, placebo-controlled, double-blind parallel-group study7,
aimed to investigate the effects of a 4-week oral intake of quercetin Phytosome®
on physiological parameters and relative subjective feelings in Japanese adults
who complained of discomfort in the eyes and nose.
After the subjects were given 250 mg of QUERCEFIT® twice daily or the placebo
for 4 weeks they experienced a favourable healthy status for their eyes and nose.
Furthermore, the quality of life of these subjects significantly improved andit has been proven a beneficial effect on immune and inflammatory processes in
the upper respiratory tract, main way in for allergens and pathogens.
Taking inspiration from the interesting Japanese study outcomes , a newinvestigation8 has been designed to deep dive the role of quercetin as a beneficialsupplementation when allergic ocular discomfort may occur.
The results show that dietary supplements may play a relevant role in the future

S P E C I F I C A T I O N S• 34-42% quercetin by HPLC • suggested dose: 250 mg once or twice a day• yellow powder for use in nutritional supplements• compliant with main worldwide markets food regulations (BELFRIT, US, EU)• high tolerability when assuming antiplatelet agents, anticoagulants or living with diabetes.9

treatment of allergic conjunctivitis, thanks to proved evidence of their effectivenessand safety.
In particular, there are evidences that supplementation with QUERCEFIT®
may favourably mitigate unbalanced ocular conditions and as stand alone
supplementation to preserve eye health over time after allergic symptomatology.
In a controlled human study on discomforts during allergy season, after 30 daysof supplementation with QUERCEFIT® plus the standard management (SM) versus
the SM alone, it has been demonstrated:10• up to 50% reduction of day intermittent discomforts frequency• up to 70% reduction of night intermittent discomforts frequency• maintenance of breath function (Peak Expiratory Flow) at physiologicallevels in mild-persistent discomforts
In another controlled human study focussing on local skin discomforts,
QUERCEFIT® was administrated for just 3 days, then followed by a local histamine
skin stimulus.
Compared to the control, only the healthy volounteers administered with theextract showed statistically significant:11• dose-dependent control of all main local conditions;• skin conditions amelioration and capillary filtration reduction

BETTER PERFORMANCE, FASTER RECOVERY
In a controlled human study12 on healthy triathlon athletes, QUERCEFIT®
demonstrated to support optimal physical performance and prompt recovery:• statistically significant results in each single triathlon test
(swimming, biking, running);• higher triathlon time reduction (-11.3%) compared to control (-3.9%)
after just 14 days of oral supplementation;• reduced discomfort related to sport activity;• lower oxidative stress (PFR) 1 hr after the final run• healthy blood levels maintenance, with a reduced UBR and LDH after prolonged sport activity.
References
1International patent application number PCT EP2018/054533 filed on 23/02/2018. 7 Yamada S. et al., Eur Rev Med Pharmacol Sci. 2022 Jun;26(12):4331-4345.
82Mazzolani F. et al., Austin J Allergy. 2022; 8(1): 1042.)
Riva A. et al., Eur J Drug Metab Pharmacokinet. 2018 Oct 16. doi: 10.1007/s
9Cesarone, M. R., et al., Minerva medica (2019).
13318-018-0517-3.
103
Riva A. et al., Minerva Cardioangiol. 2018 Sep 13. doi: 10.23736/S0026Di Pierro et al., International Journal of General Medicine 2021:14 2359–2366.
4725.18.04795-3.
4Di Pierro et al., International Journal of General Medicine 2021:14 2807–2816.
11Manuscrit submitted.
5Di Pierro et al., Frontiers in Pharmacology DOI=10.3389/fphar.2022.1096853
12Riva A. et al., Minerva Medica 2018 august;109(4):285-9.
6Rondanelli, M. et al. Life 12.1 (2022): 66.

DPR 0281 - 03/2019*02/2023

HEADQUARTERS - INDENA S.p.A.
Viale Ortles, 1220139 Milan - Italytel. +39 02 574961
INDENA BIOTECHNOLOGY (Shanghai) Co., Ltd.
Unit 810, Plaza 336, No.336 Middle XiZang Road
Shanghai 200001- China
tel. +86 21 2281 5900
INDENA Brasil Ltda
Rua Bandeira Paulista, 600
CEP 04532-001
São Paulo - Braziltel. +55 1 127 690 624

indena.com,INDENA USA Inc.
Two Union Square
601 Union Street, Suite 330
Seattle, WA 98101 - USA
tel. +1 206 340 6140

® TM

INDENA S.A.S.
7, Rue Lamennais
75008 Paris - France
tel. +33 1 45229128

trademarks of Indena S.p.A., Italy © 2023, Indena S.p.A.

INDENA JAPAN Co., Ltd.
KDDI Bld. 21F. 1-8-1 Otemachi
Chyoda-Ku Tokyo 100-0004 - Japantel. +81 3 3243 9924